Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This nationwide Finnish cohort study reveals that gout increases ischemic stroke risk in atrial fibrillation patients, with urate-lowering therapy linked to reduced stroke incidence, underscoring gout’s potential role in stroke risk s
Achieving serum urate targets <6 mg/dL (or <5 mg/dL) through Treat-to-Target (T2T) protocols significantly reduces major adverse cardiovascular events in gout patients, particularly those at high baseline risk.
The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate co
Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to hig
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12